1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,860 | 3,880 | 19:04 | |
| 3,820 | 3,960 | 20.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.03. | Singapore Facility powers Cytek's Asia-Pacific expansion | 1 | Singapore Business Review | ||
| 09.03. | Cytek Biosciences, Inc.: Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact | 1 | GlobeNewswire (USA) | ||
| 04.03. | Cytek Biosciences auf der TD Cowen Gesundheitskonferenz: Einblicke in die strategische Wachstumsplanung | 2 | Investing.com Deutsch | ||
| 27.02. | Cytek Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.02. | Cytek Biosciences outlines $205M-$212M 2026 revenue target amid record Q4 and growth in recurring revenue | 2 | Seeking Alpha | ||
| 26.02. | Cytek Biosciences: Rekordumsatz im vierten Quartal, Gewinnziel jedoch deutlich verfehlt | 1 | Investing.com Deutsch | ||
| 26.02. | Cytek Biosciences GAAP EPS of -$0.34 misses by $0.30, revenue of $62.1M beats by $3.3M | 1 | Seeking Alpha | ||
| 26.02. | Cytek Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.02. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 1 | GlobeNewswire (USA) | ||
| 13.01. | Cytek Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Cytek Biosciences Preliminary Q4 Revenue Up 8% | 1 | RTTNews | ||
| 12.01. | Cytek Biosciences, Inc.: Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results | 119 | GlobeNewswire (Europe) | FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the... ► Artikel lesen | |
| 12.11.25 | Cytek Biosciences, Inc.: TIME Recognizes Cytek Biosciences as One of America's Growth Leaders of 2026 | 5 | GlobeNewswire (USA) | ||
| 06.11.25 | Cytek Biosciences, Inc.: Cytek Muse Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year | 4 | GlobeNewswire (USA) | ||
| 06.11.25 | Cytek reaffirms $196M-$205M 2025 revenue outlook as recurring businesses accelerate | 3 | Seeking Alpha | ||
| 05.11.25 | Cytek Biosciences GAAP EPS of -$0.04 beats by $0.01, revenue of $52.3M beats by $1.16M | 5 | Seeking Alpha | ||
| 05.11.25 | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry | 1.222 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc.... ► Artikel lesen | |
| 22.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | +0,26 % | Bioxyne vs. BioNTech: Australisches MDMA-Biotech hebt Prognose nach starkem Halbjahr an | ||
| MEDIGENE | 0,030 | -15,73 % | Medigene: Zurückziehung - 18.11.2025 | ||
| STRYKER | 291,40 | +0,31 % | U.S. accuses Iran's government of operating hacktivist group that hacked Stryker | ||
| BIOFRONTERA | 2,620 | -1,87 % | Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition | ||
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| CLINUVEL | 5,810 | 0,00 % | CLINUVEL PHARMACEUTICALS LIMITED: Chair Letter to Shareholders | ||
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| GERON | 1,309 | -3,04 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARBUTUS BIOPHARMA | 3,688 | -0,05 % | Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus | WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary... ► Artikel lesen | |
| ASEP MEDICAL | 0,163 | 0,00 % | ASEP Medical Holdings Inc (2): ASEP to issue 4.48M shares for debt of $1.05-million | ||
| CELLECTAR BIOSCIENCES | 3,240 | +4,52 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 26,800 | 0,00 % | Celldex Therapeutics, Inc.: Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease . | - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved... ► Artikel lesen | |
| MYRIAD GENETICS | 4,240 | +6,53 % | Myriad Genetics, Inc.: Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer | SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,540 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| ALDEYRA | 1,569 | -2,64 % | What's Going On With Aldeyra Therapeutics Stock On Thursday? |
CYTEK BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,10 % bei einem Aktienkurs von 3,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.